Principles of antibacterial dosing in continuous renal replacement therapy

被引:205
作者
Choi, Gordon [1 ]
Gomersall, Charles D. [1 ]
Tian, Qi [1 ]
Joynt, Gavin M. [1 ]
Freebairn, Ross [1 ]
Lipman, Jeffrey [2 ]
机构
[1] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[2] Univ Queensland, Royal Brisbane & Womens Hosp, Burns Trauma & Crit Care Res Ctr, Herston, Qld, Australia
关键词
antibacterial agents; critical illness; kidney failure; acute; renal replacement therapy; pharmacokinetics; pharmacodynamics; CONTINUOUS VENOVENOUS HEMOFILTRATION; CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; SINGLE-DOSE PHARMACOKINETICS; BETA-LACTAM ANTIBIOTICS; IN-VITRO PERMEABILITY; INTENSIVE-CARE; CONTINUOUS-INFUSION; VANCOMYCIN PHARMACOKINETICS;
D O I
10.1097/CCM.0b013e3181aab3d0
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Objectives: To outline the concepts involved in optimizing antibacterial dosing in critically ill patients with acute renal failure undergoing continuous renal replacement therapy (CRRT), provide a strategy for optimizing dosing, and summarize the data required to implement the strategy. Data Sources: MEDLINE search from February 1986 to 2008. Data Extraction and Synthesis. Optimal dosing of antibacterials is dependent on achieving pharmacokinetic targets associated with maximal killing of bacteria and improved outcomes. The initial dose is dependent on the volume of distribution. Maintenance doses are dependent on clearance. Both should be adjusted according to the pharmacokinetic target associated with optimal bacterial killing, when known. The volume of distribution of some antibacterials is altered by critical illness or acute renal failure or both. Clearance by CRRT is dependent on the dose and mode of CRRT and the sieving or saturation coefficient of the drug. Both sieving and saturation coefficient are related to the plasma protein binding and thus may be altered in renal failure. Conclusions: Appropriate dose calculation requires knowledge of the pharmacokinetic target and the usual minimum inhibitory concentration of the suspected organism in the patient's locality (or if unavailable, the break point for the organism), published pharmacokinetic data (volume of distribution, non-CRRT clearance) on critically ill patients receiving CRRT (which may differ substantially from noncritically ill patients or those without renal failure), the sieving or saturation coefficient of the relevant drug in critically ill patients, the dose and mode of CRRT being used, and the actual dose of CRRT that is delivered. This large number of variables results in considerable inter- and intrapatient heterogeneity in dose requirements. This article provides basic principles and relevant data to guide the clinician in prescribing individualized dosing regimes. (Crit Care Med 2009; 37:2268-2282)
引用
收藏
页码:2268 / 2282
页数:15
相关论文
共 119 条
[1]
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]
In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[3]
Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous Venovenous Hemofiltration [J].
Arzuaga, A ;
Maynar, J ;
Gascón, AR ;
Isla, A ;
Corral, E ;
Fonseca, F ;
Sánchez-Izquierdo, JA ;
Rello, J ;
Canut, A ;
Pedraz, JL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :168-176
[4]
CIPROFLOXACIN LEVELS IN A PATIENT UNDERGOING VENOVENOUS HEMODIAFILTRATION [J].
BARRIE, JR ;
MOUSDALE, S .
INTENSIVE CARE MEDICINE, 1992, 18 (07) :437-438
[5]
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients [J].
Boereboom, FTJ ;
Ververs, FFT ;
Blankestijn, PJ ;
Savelkoul, TJF ;
van Dijk, A .
INTENSIVE CARE MEDICINE, 1999, 25 (10) :1100-1104
[6]
Böhler J, 1999, KIDNEY INT, V56, pS24
[7]
Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing [J].
Bouman, Catherine S. C. ;
Van Kan, Hendrikus J. M. ;
Koopmans, Richard P. ;
Korevaar, JohannaC. ;
Schultz, Marcus J. ;
Vroom, Margreeth B. .
INTENSIVE CARE MEDICINE, 2006, 32 (12) :2013-2019
[8]
Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates [J].
Brunet, S ;
Leblanc, M ;
Geadah, D ;
Parent, D ;
Courteau, S ;
Cardinal, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :486-492
[9]
Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients [J].
Bugge, JF .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2001, 45 (08) :929-934
[10]
Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance [J].
Burgess, DS .
CHEST, 1999, 115 (03) :19S-23S